Snapshot from Aug 17, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Regulatory / EMA accepts Lyme vaccine application
Regulatory regulatory approval

EMA accepts Lyme vaccine application

Analysis based on 6 articles · First reported Aug 14, 2026 · Last updated Aug 14, 2026

Sentiment
60
Attention
4
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The EMA acceptance boosts the commercial prospects for Pfizer and Valneva SE, with Valneva SE's stock surging nearly 16%. The vaccine addresses a significant unmet medical need, potentially creating a new market in the pharmaceutical industry.

Pharmaceuticals Biotechnology
Event Summary

The European Union — European Medicines Agency (EMA) accepted the marketing authorization application for PF-07307405, an experimental Lyme disease vaccine developed by Pfizer and Valneva SE. Clinical trials showed 70% efficacy in people aged five and older. Despite earlier disappointing trial results, the EMA's acceptance marks a major regulatory milestone. Lyme disease is the most common tick-borne illness, with no approved vaccine currently. More than 200 million people in Europe live in risk areas, and climate change may increase transmission. Valneva SE's shares surged nearly 16% on the news.

Key Actions
90 European Union — European Medicines Agency accepted application Pfizer
90 European Union — European Medicines Agency accepted application Valneva SE
Entities Involved
stock
Valneva SE
Valneva SE co-developed the vaccine; EMA acceptance is a major milestone, driving a 16% share surge and enhancing its market position.
Importance 95.0 Sentiment 85.0
stock
Pfizer
Pfizer co-developed the vaccine and received EMA acceptance, strengthening its vaccine portfolio and potential revenue stream.
Importance 90.0 Sentiment 70.0
govactor
European Union — European Medicines Agency
The EMA accepted the application for review, a key regulatory step that could lead to approval and market availability.
Importance 80.0 Sentiment 50.0
alliance
European Union
The EU's regulatory framework enabled the EMA review, potentially benefiting public health across member states.
Importance 40.0 Sentiment 50.0
per
Annaliesa Anderson
As Pfizer's chief vaccines officer, she publicly endorsed the vaccine's potential, supporting the announcement.
Importance 30.0 Sentiment 50.0
per
Thomas Lingelbach
As Valneva SE's CEO, he highlighted the milestone's significance, reinforcing the positive market reaction.
Importance 30.0 Sentiment 50.0
govactor
European Union — European Centre for Disease Prevention and Control
The ECDC provided data on Lyme disease incidence and tick season trends, supporting the vaccine's relevance.
Importance 20.0 Sentiment 50.0
Relationships
Pfizer related ↔ European Union — European Medicines Agency
Pfizer related ↔ European Union
European Union — European Medicines Agency related ↔ European Union
European Union related ↔ European Union — European Centre for Disease Prevention and Control
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.